Targretin update

At the Hambrecht & Quist Life Sciences Financial Conference today, LGND was to report interim results of an open-label, dose escalation Phase I/II trial in CTCL.

There were 9 partial responses (33 percent), defined as a 25-90 percent clearing of lesions for at least four weeks. There were no complete clinical responses, which require 90-100 percent clearing of lesions persisting for at least four weeks. ...